Fig. 14.

In vivo fluorescence and PA imaging of HA-MoS₂ conjugates. (a) IVIS imaging of PBS and HA-MoS₂ conjugates after intradermal injection into the tumor (red circle) region. (b) Quantitative fluorescence analysis of PEG-MoS₂ and HA-MoS₂ conjugates in the organs for the assessment of tumor targeting affinity (**p < 0.01, PEG-MoS₂ vs HA-MoS₂ conjugates). (c) The PA amplitude enhancement of HA-MoS₂ conjugates compared to the control (PBS) image at both 680 and 850 nm wavelengths with the depth profile of the highest signals for 240 min. (d) A photo-image and PA MAP image of mouse in respect to depth (left) and amplitude (right) before injection of HA-MoS₂ conjugates. The PA signals at 30 and 240 min after intratumoral injection of HA-MoS₂ conjugates at (e) 680 and (f) 850 nm wavelengths in respect to depth (upper) and intensity (bottom). Reprinted with permission from Ref. [293]. Copyright 2019, Advanced Healthcare Materials. g) ATPMCD (ATPMC nanoplatform loaded with DOX) for multimodality bioimaging and NIR-laser irradiation-induced chemotherapy. Reprinted with permission from Ref. [295]. Copyright 2017, Advanced Functional Materials.